{"id":"NCT01453855","sponsor":"Alcon Research","briefTitle":"Travoprost 3-Month Safety and Efficacy Study","officialTitle":"A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2011-10-18","resultsPosted":"2013-10-18","lastUpdate":"2013-10-18"},"enrollment":1099,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Travoprost ophthalmic solution, 0.003%","otherNames":[]},{"type":"DRUG","name":"Travoprost ophthalmic solution, 0.004%","otherNames":["TRAVATAN®"]}],"arms":[{"label":"Travoprost 0.003%","type":"EXPERIMENTAL"},{"label":"TRAVATAN","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate that the intraocular pressure-lowering efficacy of Travoprost 0.003% is equivalent to TRAVATAN® in adult patients with open-angle glaucoma or ocular hypertension.","primaryOutcome":{"measure":"Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)","timeFrame":"Week 2, Week 6, Month 3 (8 AM, 10 AM, 4 PM)","effectByArm":[{"arm":"Travoprost 0.003%","deltaMin":19.4,"sd":0.16},{"arm":"TRAVATAN","deltaMin":19.5,"sd":0.17}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":442},"commonTop":["Ocular hyperaemia","Conjunctival hyperaemia"]}}